Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV

Int J STD AIDS. 2024 Jul;35(8):651-653. doi: 10.1177/09564624241238813. Epub 2024 Mar 19.

Abstract

A man with advanced HIV presented with verrucous plaques 2-3 months after initial mpox infection. He received two courses of tecovirimat without resolution of initial mpox lesions and development of new lesions raising concern for resistance. He was treated with two doses of brincidofovir and demonstrated improvement 6 months later.

Keywords: HIV/AIDS and other retroviruses; Mpox; brincidofovir; case report; cidofovir; disease outbreaks; sexually transmitted infections; tecovirimat; viruses.

Publication types

  • Case Reports

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Cytosine* / analogs & derivatives
  • Cytosine* / therapeutic use
  • Disease Progression*
  • Drug Resistance, Viral*
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • HIV-1 / drug effects
  • Humans
  • Male
  • Mpox (monkeypox)
  • Organophosphonates* / therapeutic use
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • brincidofovir
  • Cytosine
  • Organophosphonates